Research ArticleCancer

ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC

See allHide authors and affiliations

Science Translational Medicine  17 Jun 2020:
Vol. 12, Issue 548, eabc4220
DOI: 10.1126/scitranslmed.abc4220

Article Information

vol. 12 no. 548

PubMed: 
Print ISSN: 
Online ISSN: 
History: 
  • Received for publication April 23, 2020
  • Accepted for publication May 29, 2020
  • .

Author Information

  1. Sangeeta Goswami1,
  2. Yulong Chen1,
  3. Swetha Anandhan1,
  4. Peter M. Szabo2,
  5. Sreyashi Basu3,
  6. Jorge M. Blando3,*,
  7. Wenbin Liu3,
  8. Jan Zhang1,
  9. Seanu Meena Natarajan1,
  10. Liangwen Xiong1,
  11. Baoxiang Guan1,
  12. Shalini Singh Yadav3,
  13. Abdel Saci2,
  14. James P. Allison3,4,
  15. Matthew D. Galsky5 and
  16. Padmanee Sharma1,3,4,
  1. 1Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  2. 2Department of Translational Medicine, Bristol Myers Squibb, Princeton, NJ 08540, USA.
  3. 3Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  4. 4Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  5. 5Division of Hematology and Medical Oncology, Department of Medicine, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, New York, NY 10029, USA.
  1. Corresponding author. Email: padsharma{at}mdanderson.org
  • * Present address: AstraZeneca, Gaithersburg, MD 20878, USA.

Altmetric

Article usage

Article usage: June 2020 to January 2021

AbstractFullPdf
Jun 202019154361228
Jul 2020313586340
Aug 20202259784
Sep 20202099970
Oct 20202105854
Nov 20202327663
Dec 20202208464
Jan 20211377245

Stay Connected to Science Translational Medicine